Key Takeaway
Wegovy and Zepbound are both FDA-approved for weight loss, but they use different active ingredients. Compare efficacy, side effects, cost, and more.
Wegovy and Zepbound are both FDA-approved specifically for chronic weight management, but Zepbound (tirzepatide) has shown greater average weight loss in clinical trials compared to Wegovy (semaglutide), making it the more potent option on paper.
This is the comparison that matters most if weight loss is your primary goal. Wegovy and Zepbound are the only two injectable GLP-1-class medications with full FDA approval for chronic weight management. Everything else in this class is either approved for diabetes and used off-label, or still in clinical trials. So when patients come to us at FormBlends asking which weight loss injection is "the best," this is really the head-to-head matchup they need to understand.
| Feature | Wegovy | Zepbound |
|---|---|---|
| Active Ingredient | Semaglutide | Tirzepatide |
| Drug Class | GLP-1 receptor agonist | Dual GIP/GLP-1 receptor agonist |
| FDA Approval Date (weight loss) | June 2021 | November 2023 |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Maximum Dose | 2.4 mg/week | 15 mg/week |
| Average Weight Loss | ~15-17% | ~18-22% |
| Cardiovascular Benefit | Yes (SELECT trial[1]) | Under investigation |
| List Price (monthly) | $1,300-$1,400/mo (brand) | $1,000-$1,200/mo (brand) |
How Wegovy Works
Wegovy uses semaglutide at doses up to 2.4 mg per week to activate GLP-1 receptors throughout the body. These receptors exist in your gut, pancreas, and brain, and activating them produces a cascade of metabolic changes that promote weight loss.
The primary mechanisms are appetite suppression and delayed gastric emptying. When you take Wegovy, you feel less hungry between meals, you get full more quickly when you do eat, and food stays in your stomach longer, which extends that feeling of satisfaction. Your brain receives stronger "I am full" signals, which makes it easier to eat less without constantly fighting cravings.
Wegovy has a five-step titration schedule: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and finally the maintenance dose of 2.4 mg. This gradual increase takes 16 to 20 weeks and helps your body adjust to the medication while minimizing GI side effects.
Beyond weight loss, Wegovy became the first GLP-1 medication to earn an FDA indication for reducing cardiovascular events in overweight and obese adults, based on the key SELECT trial.
How Zepbound Works
Zepbound uses tirzepatide, a dual-action molecule that activates both the GLP-1 and GIP receptors. While Wegovy targets one pathway, Zepbound targets two, which appears to produce a more powerful metabolic response. For a complete cost breakdown, see our best tirzepatide compounding pharmacies. For a complete cost breakdown, see our cheapest tirzepatide options.
View data table
| Category | Overall Value Score | Detail |
|---|---|---|
| FormBlends | 92 | From $299/mo, physician-led |
| Hims/Hers | 78 | Consumer brand, varies |
| Ro | 75 | Telehealth platform |
| Calibrate | 70 | Metabolic health focus |
The GIP receptor activation adds several effects beyond what GLP-1 alone provides. GIP signaling may improve how your body metabolizes fat, enhance insulin sensitivity in adipose tissue, and work together effectively with GLP-1 to further suppress appetite . This combination is believed to be the reason Zepbound produces more weight loss than Wegovy in clinical data.
Zepbound's titration moves through six dose levels: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. This gives doctors more flexibility to find the dose that balances effectiveness with tolerability for each patient. Not every patient needs to reach the maximum 15 mg dose to see excellent results.
Efficacy Comparison: Weight Loss Results
Both medications deliver significant weight loss, but Zepbound holds a numerical edge.
Not sure which GLP-1 is right for you?
Take a 2-minute assessment and get a personalized recommendation after licensed provider review.
Take the Assessment →In the STEP 1 trial[2], Wegovy patients lost an average of 14.9% of their body weight over 68 weeks . About one-third of participants lost 20% or more of their starting weight. The STEP program included several trials across different populations, and results consistently fell in the 12-17% range depending on the dose and patient group.
Zepbound's SURMOUNT-1 trial[3] showed more dramatic results: an average of 22.5% body weight[3] loss at the 15 mg dose and 19.5% at the 10 mg dose over 72 weeks . Nearly 40% of participants on the highest dose lost more than 25% of their starting weight.
While there hasn't been a large, published head-to-head randomized trial comparing Wegovy 2.4 mg directly to Zepbound 15 mg, cross-trial comparisons strongly suggest that tirzepatide produces roughly 5-7 percentage points more weight loss than semaglutide. For a 250-pound person, that difference could translate to an additional 12-18 pounds of weight loss.
Both drugs show continued weight loss over the full study period, with the most rapid loss occurring in the first 6-9 months and then gradually plateauing as patients approach their new equilibrium weight.
Side Effects Comparison
The side effect profiles are broadly similar, since both drugs work through related pathways:
- Nausea: The number one reported side effect for both. In clinical trials, nausea affected roughly 24-44% of Wegovy users and 24-33% of Zepbound users.
- Diarrhea: Reported in 15-30% of patients for both medications.
- Vomiting: More frequent during dose escalation for both.
- Constipation: Somewhat more commonly reported with tirzepatide.
- Abdominal discomfort: Related to slower gastric emptying. common with both.
Serious risks include pancreatitis, gallbladder events (especially in patients losing weight rapidly), kidney injury, and the theoretical thyroid tumor risk from animal studies. Both medications carry the same boxed warning regarding thyroid C-cell tumors.
Discontinuation rates due to adverse events in the major clinical trials were roughly similar (6-7% for both), suggesting that neither drug has a clear tolerability advantage overall.
Our clinical team at FormBlends provides hands-on support through the titration phase for either medication. We find that proactive side effect management, including dietary guidance, hydration reminders, and timing recommendations, makes a significant difference in how patients experience the early weeks of treatment. Most patients settle into a comfortable routine within the first month or two at their maintenance dose.
Cost Comparison
Both Wegovy and Zepbound are premium-priced medications. Wegovy's list price is approximately $1,300-$1,400/mo (brand) per month. Zepbound lists at approximately $1,000-$1,200/mo (brand) per month.
Insurance coverage for anti-obesity medications remains a significant barrier for many patients. While coverage has been expanding, many commercial plans and most Medicare Part D plans don't cover weight loss drugs. Some state Medicaid programs have started covering these medications, but availability varies widely.
Both Novo Nordisk and Eli Lilly offer savings programs, and Eli Lilly has been particularly aggressive with direct-to-consumer pricing through its LillyDirect program. Still, out-of-pocket costs remain prohibitive for many patients.
FormBlends addresses this gap by offering compounded semaglutide and compounded tirzepatide through physician-supervised programs at a fraction of the brand-name cost. Our compounded formulations use the prescribed active pharmaceutical ingredient and are prepared by licensed 503B compounding pharmacies.
Who Is Wegovy Best For?
- Patients who want a proven weight loss medication with cardiovascular risk reduction benefits
- Those who already respond well to semaglutide and are achieving their goals
- Patients whose insurance covers Wegovy specifically
- Anyone who prefers a medication with more years of real-world safety data
- Patients who value the additional cardiovascular protection from the SELECT trial
Who Is Zepbound Best For?
- Patients looking for the most potent available weight loss medication
- Those who tried semaglutide and reached a plateau before meeting their goal
- Patients with a high starting BMI who may benefit from the greater weight reduction
- Anyone who hasn't responded adequately to single-receptor GLP-1 therapy
- Patients who can access Zepbound through insurance or direct savings programs
Medical References
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. [PubMed | ClinicalTrials.gov | DOI]
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. [PubMed | ClinicalTrials.gov | DOI]
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. [PubMed | ClinicalTrials.gov | DOI]
Frequently Asked Questions
FormBlends
FormBlends is a U.S. telehealth platform that prescribes compounded semaglutide and tirzepatide. Patients complete an online intake, a licensed provider reviews eligibility, and medication ships from a 503A compounding pharmacy. Monthly pricing starts at $199. Start your intake.
Which produces more weight loss, Wegovy or Zepbound?
Zepbound (tirzepatide) produces greater average weight loss in clinical trials, roughly 18-22% versus 15-17% for Wegovy (semaglutide). Individual results vary, but the trend consistently favors tirzepatide across multiple studies and patient populations.
Can I switch from Wegovy to Zepbound?
Yes, under medical supervision. Because the two drugs contain different active ingredients, switching requires starting Zepbound at its initial 2.5 mg dose and titrating up. Your doctor can advise on timing and the best transition approach.
Are there cheaper alternatives to Wegovy and Zepbound?
Yes. Compounded versions of both semaglutide and tirzepatide are available through telehealth providers like FormBlends. These formulations use the prescribed active pharmaceutical ingredient and are prepared by licensed pharmacies at significantly lower prices.
Do I need a BMI of 30 to qualify?
The FDA-approved criteria for both medications require a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related health condition. But prescribing decisions are made individually by your physician.
How do I decide between Wegovy and Zepbound?
Consider your weight loss goals, health conditions, insurance coverage, and prior medication experience. Patients seeking maximum weight loss may lean toward Zepbound, while those who value cardiovascular risk reduction or are already succeeding on semaglutide may prefer Wegovy. A physician can help you weigh these factors.
Both Wegovy and Zepbound represent the best that modern weight loss medicine has to offer. If you're starting from scratch with no preference, Zepbound's stronger clinical data may make it the default recommendation. But if you value cardiovascular protection, have had success on semaglutide, or have better insurance coverage for Wegovy, it remains an excellent choice. The gap between these two medications is smaller than either one's gap over every other weight loss option on the market.
Not sure which medication is right for you? Start your free consultation with FormBlends today. Our board-certified physicians specialize in weight loss medicine and will recommend the best approach based on your unique health profile and goals.